Show simple item record

Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.

dc.contributor.authorTastekin, Didem
dc.contributor.authorSakar, Burak
dc.contributor.authorKarabulut, Senem
dc.contributor.authorDogan, Izzet
dc.date.accessioned2021-12-10T10:18:29Z
dc.date.available2021-12-10T10:18:29Z
dc.date.issued2021
dc.identifier.citationDogan I., Tastekin D., Karabulut S., Sakar B., "Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_37d1ab36-46db-4b7c-a548-0cad3ceda14f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169634
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.3_suppl.366
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleTemozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentİstanbul Teknik Üniversitesi , ,
dc.identifier.volume39
dc.identifier.issue3
dc.contributor.firstauthorID2608099


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record